ADC Therapeutics SA
(NYSE:ADCT)
$
2.93
-0.05 (-1.68%)
Market Cap: 283.30 Mil
Enterprise Value: 112.41 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 46/100 ADC Therapeutics SA at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021 / 01:20PM GMT
Release Date Price:
$27.16
(+1.19%)
Brian Cheng
Cantor Fitzgerald, L.P. - Analyst
Good morning. Thank you for joining us today at our annual Global Healthcare Conference. I am Brian Cheng. I'm the Senior Biotech Analyst here at Cantor. It is my pleasure to introduce your next management team from ADC Therapeutics. Joining us is their CEO, Chris Martin.
Chris, welcome, and thank you so much for joining us today.
Chris Martin
ADC Therapeutics SA - CEO, Co-Founder & Director
Pleasure, Brian, and thank you.
Brian Cheng
Cantor Fitzgerald, L.P. - Analyst
Great. So let's start off with a quick presentation from the management team and then we'll transition to our fireside chat.
Chris, the floor is yours.
Chris Martin
ADC Therapeutics SA - CEO, Co-Founder & Director
Thanks, Brian. I will just use a couple of slides to give you a very quick background. So for the normal forward-looking statements -- so we've had, as you know, the recent approval of ZYNLONTA. And that is in the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot